Pancreatic ductal adenocarcinoma is one of the deadliest cancer types, with a five-year survival rate of 13%. There are only two treatment regimens available with limited efficacy. Pancreatic cancers do not respond to immunotherapy ...
17 hours ago
0
4
An AI model (REDMOD) can pick up the very early subtle tissue changes of pancreatic ductal adenocarcinoma, the most common form of pancreatic cancer, which conventional imaging and the human eye find difficult to detect, ...
Apr 28, 2026
0
27
A new study by researchers at Fox Chase Cancer Center focusing on pancreatic cancer has shown that a new scoring system can provide a single numerical value that reflects whether the tumor microenvironment, the biological ...
Apr 24, 2026
0
3
As we age, our cells accumulate genetic changes—mutations—some of which open the door to cancer. Scientists call these mutations "oncogenic," meaning "tumor-producing." By our senior years, we each may harbor as many as 100 ...
Apr 15, 2026
0
13
Pancreatic ductal adenocarcinoma is the most common type of pancreatic cancer and has a low five-year survival rate. It begins with a reversible state called acinar-to-ductal metaplasia, where cells can heal after injury ...
Apr 3, 2026
0
16
Tumors driven by cancer-driving KRAS mutations are often susceptible to ferroptosis, a type of cell death that can be harnessed for cancer therapy. Given that more than 95% of pancreatic ductal adenocarcinomas (PDACs) harbor ...
Apr 2, 2026
0
6
A team from the Research Institute of the McGill University Health Center (The Institute), led by Jean-Jacques Lebrun, Ph.D., has identified a protein that pancreatic cancer cells rely on to survive and grow. This discovery ...
Mar 31, 2026
0
6
Obesity increases the body's need for insulin, forcing cells in the pancreas known as beta cells to ramp up insulin production to maintain blood sugar levels. Scientists have thought that this excessive insulin secretion ...
Mar 18, 2026
0
9
Clinically available KRAS inhibitors mainly target G12C, which is rare in PDAC and often acquires resistance. Oncogenic KRAS inactivates RB1 via CDK4/6, while RB1 mutation is rare. Thus, CDK4/6 inhibition offers an indirect ...
Mar 13, 2026
0
9
A new preclinical study in mice shows that precancerous cells in the pancreas can be eliminated before they have the chance to become tumors. Using an experimental therapy to target microscopic precancerous lesions in the ...
Mar 12, 2026
0
486
